Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Ideaya Biosciences Inc.
Sponsor

Ideaya Biosciences Inc.

United States 5000 Shoreline Court Suite 300, 94080-1956, United States

About the sponsor

Research activity is centered on uveal melanoma, with studies addressing both early-stage eye cancer and metastatic disease. The sponsor’s programs include treatment strategies for HLA-A2 negative metastatic cases and disease control in primary ocular tumors.

  • Primary uveal melanoma
  • Metastatic uveal melanoma
  • HLA-A2 negative disease

Key interests include preservation of vision, prevention of enucleation, and tumor control in ocular malignancies.

About Specializations

Ideaya Biosciences Inc. runs clinical trials in conditions such as Uveal melanoma, Neoplasm, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

5 clinical trials

Uveal melanoma

Recruiting

A Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Darovasertib
  • Sponsor:Ideaya Biosciences Inc.

Neoplasm

Not yet recruiting

Study of IDE849, IDE‑161 and durvalumab evaluating safety and efficacy in patients with DLL3‑positive tumors including small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Ideaya Biosciences Inc.

Uveal melanoma

Not yet recruiting

Study of Darovasertib and Crizotinib for Patients with HLA-A2 Negative Metastatic Uveal Melanoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Ideaya Biosciences Inc.

Uveal melanoma

Not recruiting

Study of Darovasertib and Crizotinib for Patients with Metastatic Uveal Melanoma Who Are HLA-A2 Negative

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Ideaya Biosciences Inc.

Uveal melanoma

Not recruiting

Study of Darovasertib for Patients with Localized Uveal Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darovasertib
  • Sponsor:Ideaya Biosciences Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.